COMPANY
Ocular Therapeutix
FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3
Since the raise (Sep 30, 2025): 18 of 18 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Research Associate II, Quality Control | Bedford, MA | Oct 21, 2026 | Oct 22, 2026 |
| ED/VP GPO and Corporate Accounts | Remote | Oct 6, 2026 | Oct 9, 2026 |
| ED/VP Patient and Provider Support | Remote | Oct 6, 2026 | Oct 9, 2026 |
| Retina Corporate Accounts Director | Remote | Oct 6, 2026 | Oct 9, 2026 |
| VP, Access Strategy and Payer Engagement | Remote | Oct 6, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (18 open jobs at last check). source ↗
- Trial start Phase 3: Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023- source ↗
- Trial start Phase 3: A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy source ↗
- Raise Follow-on offering: $475M (total, as published), announced Sep 30, 2025. Source: SEC filing. source ↗
- FDA FDA New indication / efficacy supplement: DEXTENZA (dexamethasone) — NDA208742/13, Apr 7, 2025. Applicant at approval: Ocular Therapeutix, Inc. source ↗
- Trial start Phase 3: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration source ↗
- Trial start Phase 3: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration source ↗
- Trial start Phase 2: OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) source ↗
- Trial start Phase 1: Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy source ↗
- Trial start —: An Observational, Qualitative Study Assessing Eye Drop Administration source ↗
- Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) source ↗
- Trial start Phase 1: Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration source ↗
- Trial start Early phase 1: A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects source ↗
- Trial start Phase 2: To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease source ↗
- Trial start Phase 3: A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract source ↗
- Trial start Phase 1/Phase 2: Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease. source ↗
- Trial start Phase 3: A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis source ↗
- Trial start Phase 1: CLN-0046: Treatment of AMD Subjects With OTX-TKI source ↗
- Trial start Phase 3: A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert source ↗
- Trial start Phase 1: CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension source ↗
- Trial start 3: Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT source ↗
- Trial start 3: OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery source ↗
- Trial start 3: OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis source ↗
- Trial start 3: OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis source ↗
- Trial start 2: OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye source ↗
Upcoming milestones
- Jan 8, 2027 (ESTIMATED) · Phase 3 · Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration · NCT06495918
- 2027-03 (ESTIMATED) · Phase 3 · A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy · NCT07235085
- Aug 1, 2030 (ESTIMATED) · Phase 3 · Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 o · NCT07516132
Open jobs 18
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Research Associate II, Quality Control | Bedford, MA | Oct 21, 2026 | Oct 22, 2026 | Not stated |
| ED/VP GPO and Corporate Accounts | Remote | Oct 6, 2026 | Oct 9, 2026 | Executive |
| ED/VP Patient and Provider Support | Remote | Oct 6, 2026 | Oct 9, 2026 | Executive |
| Retina Corporate Accounts Director | Remote | Oct 6, 2026 | Oct 9, 2026 | Senior |
| VP, Access Strategy and Payer Engagement | Remote | Oct 6, 2026 | Oct 9, 2026 | Executive |
| Associate Director, HR Operations & Total Rewards | Bedford, MA | Oct 5, 2026 | Oct 9, 2026 | Senior |
| Medical Affairs & HEOR, National Account Director | Bedford, MA | Sep 28, 2026 | Oct 9, 2026 | Senior |
| Senior Director, Facilities | Bedford, MA | Sep 22, 2026 | Oct 9, 2026 | Senior |
| Manager, ERP Master Data Management (MDM) | Bedford, MA | Sep 22, 2026 | Oct 9, 2026 | Mid |
| Maintenance Field Manager | Bedford, MA | Sep 21, 2026 | Oct 9, 2026 | Mid |
| AD, Commercial Packaging and 3PL Inventory Management | Bedford, MA | Sep 21, 2026 | Oct 9, 2026 | Senior |
| Corporate Account Director -DEXTENZA | Remote | Sep 18, 2026 | Oct 12, 2026 | Senior |
| Associate Director, Validation | Bedford, MA | Sep 4, 2026 | Oct 9, 2026 | Senior |
| Key Account Manager - Northern LA | Los Angeles, CA | Aug 21, 2026 | Oct 9, 2026 | Mid |
| Assistant Corporate Controller | Bedford, MA | Jun 26, 2026 | Oct 9, 2026 | Mid |
| Process Engineer, MSAT | Bedford, MA | Jun 25, 2026 | Oct 9, 2026 | Mid |
| Key Account Manager - Minneapolis, MN | Minneapolis, MN | May 26, 2026 | Oct 9, 2026 | Mid |
| Manufacturing Operator - hiring multiple positions! | Bedford, MA | Mar 23, 2026 | Oct 9, 2026 | Entry |
Funding
- Follow-on offering: $475M (total, as published), announced Sep 30, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 33
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05335122 | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT) | Phase 2 | Completed | Mar 16, 2022 | Jan 24, 2024 (actual) |
| NCT07516132 | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study | Phase 3 | Recruiting | Apr 27, 2026 | Aug 1, 2030 (estimated) |
| NCT07235085 | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy | Phase 3 | Recruiting | Nov 17, 2025 | 2027-03 (estimated) |
| NCT06495918 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Phase 3 | Active, not recruiting | Nov 27, 2024 | Jan 8, 2027 (estimated) |
| NCT06223958 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration | Phase 3 | Active, not recruiting | Jan 29, 2024 | Apr 29, 2026 (estimated) |
| NCT04360174 | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension | Phase 1 | Completed | Apr 25, 2018 | May 24, 2021 (actual) |
| NCT05814757 | OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) | Phase 2 | Completed | May 11, 2023 | May 22, 2024 (actual) |
| NCT03630315 | CLN-0046: Treatment of AMD Subjects With OTX-TKI | Phase 1 | Completed | Feb 18, 2019 | Jan 10, 2024 (actual) |
| NCT04539548 | A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract | Phase 3 | Completed | Sep 4, 2020 | Dec 21, 2023 (actual) |
| NCT04989699 | Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration | Phase 1 | Completed | Jul 28, 2021 | Feb 6, 2023 (actual) |
| NCT05695417 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy | Phase 1 | Unknown status (ClinicalTrials.gov) | Jan 15, 2023 | 2024-01 (estimated) |
| NCT04362670 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease. | Phase 1/Phase 2 | Completed | Apr 23, 2020 | Aug 11, 2021 (actual) |
| NCT04061044 | A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert | Phase 3 | Completed | Jul 10, 2018 | Feb 10, 2020 (actual) |
| NCT04747977 | To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease | Phase 2 | Completed | Feb 12, 2021 | Aug 11, 2021 (actual) |
| NCT04945824 | A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects | Early phase 1 | Terminated | Jun 1, 2021 | Nov 1, 2022 (actual) |
| NCT05307081 | An Observational, Qualitative Study Assessing Eye Drop Administration | Not listed | Unknown status (ClinicalTrials.gov) | Apr 21, 2022 | 2023-07 (estimated) |
| NCT01666210 | Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery | II | Completed | 2012-10 | 2013-08 (actual) |
| NCT02914509 | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT | 3 | Completed | Nov 7, 2016 | Mar 30, 2019 (actual) |
| NCT04050865 | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis | Phase 3 | Completed | Aug 5, 2019 | Feb 28, 2020 (actual) |
| NCT00774228 | I-ZIP Ocular Bandage Pivotal Study | Not phased (device or behavioral study) | Completed | 2008-10 | 2009-07 (actual) |
| NCT02988882 | OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis | 3 | Completed | 2015-06 | Apr 27, 2016 (actual) |
| NCT02309736 | OTX-14-002: Device Exposure Registry | Not listed | Withdrawn | Not listed | 2020-04 (estimated) |
| NCT02034019 | Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery | 3 | Completed | 2014-02 | 2014-12 (actual) |
| NCT02089113 | OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery | 3 | Completed | 2014-04 | 2015-01 (actual) |
| NCT02062905 | OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis | 2 | Completed | 2014-03 | 2014-08 (actual) |
| NCT02445326 | OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis | 3 | Completed | 2015-04 | 2015-08 (actual) |
| NCT02468700 | OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye | 2 | Completed | 2015-01 | 2015-08 (actual) |
| NCT02736175 | OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery | 3 | Completed | 2015-10 | 2016-05 (actual) |
| NCT02312544 | Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension | 2 | Completed | 2014-11 | 2015-09 (actual) |
| NCT01845038 | Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma | Phase 1 | Completed | 2013-04 | 2014-03 (actual) |
| NCT01498224 | ReSure Sealant Pivotal Study | Phase 3 | Completed | 2011-12 | 2012-11 (actual) |
| NCT02310815 | ReSure Sealant Post Approval Study | Not listed | Completed | 2014-12 | 2016-02 (actual) |
| NCT01800175 | Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug | Phase 1 | Unknown status (ClinicalTrials.gov) | 2013-02 | 2016-12 (estimated) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: DEXTENZA (dexamethasone) — NDA208742/13, Apr 7, 2025. Applicant at approval: Ocular Therapeutix, Inc. source ↗
Connect
See your connections at Ocular Therapeutix on LinkedIn (search by name, results not checked)